Harvard Medical School Curriculum Vitae
`
`Date Prepared: April 13, 2018
`
`Name:
`
`Aaron B. Waxman, M.D., PhD.
`
`Office Address:
`
`Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston,
`MA
`
`Home Address:
`
`673 Centre Street, Newton, MA 02458
`
`Work Phone:
`
`617-525-9783
`
`Work Email:
`
`abwaxman@partners.org
`
`Work FAX:
`
`617-264-683
`
`Place of Birth:
`
`London, Ontario, Canada
`
`Education
`
`1978
`
`198?
`1992
`
`BS
`
`PhD.
`MD.
`
`Postdoctoral Training
`192 — 9f92
`lntem
`992 — 6f94
`Resident
`
`W94 — 6E9?
`
`Fellow
`
`7/87 — 6f88
`
`Postdoctoral
`Associate
`
`6/88 — 12f90 Postdoctoral
`Associate
`
`Zoology
`
`Anatomy and Neuroscience
`Medicine
`
`The George Washington University,
`Washington, DC
`Albany Medical College, Albany, NY
`Yale University School of Medicine,
`New Haven, CT
`
`Internal Medicine
`Internal Medicine
`
`Pulmonary and Critical
`Care Medicine
`
`Yale New Haven Hospital
`Yale New Haven Hospital
`Yale University School of Medicine
`
`Neuroanatomy
`
`Yale University School of Medicine
`
`Molecular Neurobiology
`
`Howard Hughes Medical Institute and
`Yale University School of Medicine
`
`Faculg Academic Appointments
`Medicine
`1997r — 1998
`Instructor
`1998 — 2000 Assistant Professor Medicine
`
`2000 — 2001 Assistant Professor Medicine
`2001 — 2011 Assistant Professor Medicine
`2011 -
`Associate Professor Medicine
`
`Yale University School of Medicine
`Yale University School of Medicine
`Tufts University School of Medicine
`Harvard Medical School, Boston, MA
`Harvard Medical School, Boston, MA
`
`Appointments at Hospitalszffiliated Institutions
`
`1993-1994
`1994-1995
`1995-199?
`1995-1999
`3196-1299
`7:97-12:99
`
`Attending Physician Emergency Room
`Attending Physician Emergency Medicine
`Attending Physician Emergency Medicine
`Attending Physician Emergency Medicine
`Attending Physician Pulmonary Critical Care
`Attending Physician PulmOnary Critical Care
`
`West Haven VA HOSpital
`Bristol Hospital, Bristol CT
`Yale New Haven Hospital
`Hospital of Saint Raphael
`West Haven VA Hospital
`Yale New Haven Hospital
`
`1
`
`lPR2021-00406
`
`United Therapeutics EX2002
`Page 1 of 42
`
`IPR2021-00406
`United Therapeutics EX2002
`Page 1 of 42
`
`

`

`Attending Physician
`UGO-12ml
`Attending Physician
`1:00—12:01
`Attending Physician
`lf00-12f09
`12’02 — 11f09 Attending Physician
`08t13— 0'?! l6 Attending Physician
`11;”09 -
`ConSulting Staff
`112’09 -
`Associate Physician
`
`Pulmonary Critical Care
`Pulmonary Critical Care
`Emergency Medicine
`Pulmonary Critical Care
`Cardiology
`Medical Oncology
`Pulmonary Critical Care
`
`Winchester Hospital
`New England Medical Center, Boston
`Faulkner Hospital, Boston, MA
`Massachusetts General Hospital
`Boston Children’s Hospital
`Dana-Farber Cancer Institute
`
`Brigham and Women’s Hospital
`
`Maior Administrative Leadership Positions
`
`Local
`
`1998-1999
`
`1999-2001
`200]
`2005-2009
`2009 -
`201 1-
`
`2012-2015
`
`2013-
`
`Associate Medical Director, Medical Intensive
`Care Unit
`
`Yale New Haven Hospital
`
`Director of Bronchoscopy Services
`Medical Director of Respiratory Therapy
`Director, Pulmonary Vascular Disease Program
`Director, Pulmonary Vascular Disease Program
`Director, Dyspnea and Performance Evaluation
`Center
`
`Yale New Haven Hospital
`New England Medical Center
`Massachusetts General Hospital
`Brigham and Women’s Hospital
`Brigham and Women’s Hospital
`
`Associate Program Director, PCCM fellowship
`training program
`Executive Director, Center for Pulmonary Heart
`Diseases
`
`Brigham and Women’s Hospital and
`Harvard Medical School
`
`Brigham and Women’s Hospital Heart
`and Vascular Center
`
`Committee Service
`
`Local
`
`1983-1984
`
`Curriculum Committee
`1983-1984
`
`1 993-1994
`
`Education Committee
`
`1993—1994
`
`1996-1999
`
`Fellowship Curriculum Committee
`
`1996-] 999
`
`1996-1999
`
`Fellowship Admissions Committee
`
`1996—1999
`
`1996-1999
`
`Bronchoscopy Quality Assurance Committee
`1996-1999
`
`2002-2003
`
`Fellowship Admissions Committee
`
`2004
`
`Task Force on Sepsis Management and Early
`Goal Directed Therapy, Critical Care
`Committee
`
`Albany Medical College.
`Member, Graduate Studies Program
`Yale University School of Medicine,
`Department of Medicine
`Member
`
`Yale University School of Medicine,
`Section of Pulmonary and Critical Care
`Chairperson
`Yale University School of Medicine,
`Section of Pulmonary and Critical Care
`Member
`
`Yale New Haven Hospital
`Chairperson
`Yale University School of Medicine
`Member
`
`Massachusetts General Hospital
`
`2004
`
`Chairperson
`
`lPR2021-00406
`
`United Therapeutics EX2002
`Page 2 of 42
`
`IPR2021-00406
`United Therapeutics EX2002
`Page 2 of 42
`
`

`

`2004
`
`Task Force on the Use of Albumin in
`
`Massachusetts General Hospital
`
`Resuscitation in Shock, Critical Care
`Committee
`2004
`
`Optimum Care Committee
`2004-2009
`
`Clinical Research Council,
`2007-2009
`
`Acute Pulmonary Embolism Program
`
`2004-2009
`
`2002-2009
`
`2014
`
`National and International
`
`2003 -201 1
`
`Partnership for Excellence in Critical Care
`
`2008-2010
`
`Biomarkers in Pulmonary Vascular Disease
`
`2012, 2013,
`2014
`
`International Right Heart Failure Summit
`Annual Meeting
`
`2013-2016
`
`International Right Heart Failure Foundation
`
`2013
`
`2014
`
`2017
`
`Pulmonary Vascular Research Institute - joint
`Symposium of the Excellence Cluster
`Cardiopulmonary System (ECCPS) and
`Pulmonary Vascular Research Institute (PVRI)
`in Bad Nauheim, Germany
`Pulmonary Vascular Research Institute — 8th
`World Congress
`
`Pulmonary Vascular Research Institute —
`Grants Advisory Committee
`
`Chairperson
`Massachusetts General Hospital
`Member
`
`Massachusetts General HOSpital
`Member
`
`Director of Steering Committee,
`Brigham and Women’s Hospital
`
`One of the founding members with a
`leadership role in a number of quality
`improvement initiatives
`
`Chair of Flaming Committee for
`International Meeting
`
`Co-Chair of organizational committee
`developing an international expert
`forum focused on pathophysiologic and
`clinical issues focused on right heart
`failure from multiple pathways.
`
`Founding member and Chair of the
`Scientific Steering Committee
`Member of the scientific committee
`
`responsible for meeting organization
`and content.
`
`Director of Scientific Affairs and head
`
`of committee reSponsibie for meeting
`organization and content.
`Formulation, administration, review,
`and distribution of research funds as
`
`part of the PVRI and Dinosaur Trust,
`UK
`
`Professional Societies
`
`1983-1992
`
`American Association of Anatomists
`
`1996-
`1996-
`
`1996-
`
`Society for Critical Care Medicine
`American College of Physicians
`2013
`
`American College of Chest Physicians
`1998-
`
`Fellow
`
`Fellow
`
`lPR2021-00406
`
`United Therapeutics EX2002
`Page 3 of 42
`
`IPR2021-00406
`United Therapeutics EX2002
`Page 3 of 42
`
`

`

`2006-200?
`
`1996-
`
`American Thoracic Society
`ATS Pulmonary Circulation Assembly
`Program Committee for 2012.
`
`2004-
`
`Pulmonary Hypertension Association
`2004-
`
`2008-2 01 0
`
`2011-2012
`
`2006-2008
`
`2008
`
`2008—2014
`2009
`2013
`2014-2015
`
`Pulmonary Arterial Hypertension Education
`Initiative
`2006-2008
`
`European Respiratory Society
`Wilderness Medical Society
`Pulmonary Vascular Research Institute
`Pulmonary Vascular Research Institute
`Pulmonary Vascular Research Institute
`
`2017
`
`Pulmonary Vascular Research Institute
`
`Member, Chest Journal CME Task
`Force
`
`Program committee to plan the
`Pulmonary Circulation Assembly’s
`sessions for the 2013 International
`
`Conference, May 17—24 in Philadelphia,
`PA. Review abstracts submitted to the
`
`Assembly and help program acceptable
`abstracts into the appropriate format
`
`Member, Clinicians and Researchers
`
`Scientific Leadership Council,
`Scientific Sessions Committee.
`
`Committee responsible for planning
`structure and content of sessions at
`2010 PHA International Conference
`
`Scientific Leadership Council,
`Scientific Sessions Committee.
`
`Committee responsible for planning
`structure and content of sessions at
`2012 PHA International Conference
`
`Member, Educational Council
`Member
`Member
`Fellow
`
`Chair, Right Heart Failure Task Force
`Director, Scientific Affairs — Organize
`the annual international meeting,
`oversee all educational activities of the
`
`institute
`
`Organized the first PVRI Symposium
`on PAH for the Cuban Society of
`Cardiology and the Hospital Hermanos
`Ameijeiras
`
`Editorial Activities
`
`Ad Hoc Reviewer
`
`Brain, Pediatric Research, Journal of Intensive Care Medicine, American Journal of Medicine, American
`
`Journal of Physiology: Lung Cellular and Molecular Physiology, Chest, American Journal of Respiratory
`Cell and Molecular Biology, Cytokine, Journal of Experimental Medicine, Respiratory Medicine,
`American Heart Journal, Circulation, Thrombosis and Hemostasis, Circulation Heart Failure, Journal of
`Heart and Lung Transplantation, Circulation Research, Pulmonary Circulation
`
`Other Editorial Roles
`
`lPR2021-00406
`
`United Therapeutics EX2002
`Page 4 of 42
`
`IPR2021-00406
`United Therapeutics EX2002
`Page 4 of 42
`
`

`

`2010
`2012
`
`Editorial Board
`Editorial Board
`
`Honors and Prizes
`
`Pulmonary Circulation
`The Journal of Heart and Lung
`Transplantation
`
`Trustee Scholarship
`Dean’s Award and Prize for
`
`Albany Medical College
`Albany Medical College
`
`Academic
`
`Leadership
`
`Leadership
`Dean’s Award and Prize for
`
`Excellence in Teaching
`Alumni Association Medal
`and Prize
`
`Albany Medical College
`
`Teaching
`
`Albany Medical College
`
`Research and Teaching
`
`Sigma Xi
`
`Sigma Xi Research Society
`
`American College of Chest
`Physicians
`Merck and Company, Inc
`
`Yale University School of
`Medicine
`
`Tufts Medical Center
`
`Tufts Medical Center
`
`Brigham and Women’s
`Hospital
`
`Excellence in scientific
`
`investigation
`Excellence in scientific
`
`investigation
`Excellence in scientific
`
`investigation
`Excellence in Teaching and
`Mentorship
`
`Recognition for outstanding
`patient care
`Excellence in Teaching and
`Mentorship
`
`Research and Clinical
`
`Brigham and Women’s
`Hospital
`Harvard Medical School
`
`Development of Right Heart
`Failure Team
`Nominee
`
`1982-198?
`
`1985, 1986
`
`1985, 1986
`
`1987
`
`1987
`
`199'?
`
`l999
`
`l 999
`
`200]
`
`2002
`
`2011
`
`2014
`
`2014
`
`Young Investigator” 5
`Awards
`
`Merck ReSpiratory Young
`Investigator
`Fellowship Teaching
`Award, Pulmonary Critical
`Care Fellowship
`Oliver Smith Award
`
`Pulmonary Critical Care
`Fellows Award for
`
`Teaching and Mentorship
`Susan & Katherine
`
`McArthur—Radovsky
`Award
`Partners in Excellence
`Award
`
`Excellence in Mentoring
`Award
`
`Report of Funded and Unfunded Proiects
`
`Funding Information
`
`Past
`
`199?-1999
`
`1998-2004
`
`IL-Il protection from hyperoxic lung injury
`Parker B. Francis Fellowship Award
`Role: Principle Investigator
`Goals: Characterize the protective effects of IL-1 1 pretreatment in the setting of hyperoxic
`injury. Characterize the mechanism(s) of lL—l l-induced protection in the setting of
`hyperoxic injury.
`Mechanisms of IL-11 protection from hyperoxic lung injury
`Mentored Clinical Scientist Research Award (K08 HLO3888-01)
`Role: Principle Investigator
`
`IPR2021-00406
`
`United Therapeutics EX2002
`Page 5 of 42
`
`IPR2021-00406
`United Therapeutics EX2002
`Page 5 of 42
`
`

`

`1999-2001
`
`2004-2009
`
`2006-2009
`
`2007-2009
`
`2007-201]
`
`2007-201]
`
`2008-2012
`
`2011-2013
`
`Goals: Compare the expression of apoptosis regulators in IL-1 1 transgene (+) and
`littermate control mice before and after exposure to 100% oxygen. Establish an in vitro
`system that can be used to define the mechanism of hyperoxia- (oxidant) induced apoptosis
`and the protective effects of IL-1 1.
`Mechanisms of IL-1 1 protection from hyperoxic lung injury
`American Lung Association Research Grant
`Role: Principle Investigator
`Goals: Define the kinetics and the specific cell populations that undergo apoptosis in
`hyperoxic lung injury. Define the alterations in apoptosis regulatory processes and,
`characterize the alterations in regulators of apoptosis induced by IL—1 1 and determine their
`role in mediating IL-l l-induced protection in lung injury.
`Interleukin-1 1 and Interleukin-6 protection from oxidant mediated lung injury
`NIH R01 Research Grant R01 HLOT4859
`
`Role: Principle Investigator
`Goals: Characterize the signal transduction pathways that mediate IL-1 1 and IL-6 induced
`protection from oxidant stress in vitro and examine the relationship to upregulation of
`mediators of cell death. Evaluate the contribution(s) of Bel 2 family proteins to protection
`of pulmonary epithelial and microvascular endothelial cells in vitro. Evaluate the
`contribution(s) of Bel 2 family proteins to protection in vivo.
`MGH Pulmonary Vascular Development Fund
`Internal award for research on pathogenesis of pulmonary hypertension
`Role: Principle Investigator
`Evaluation of the role of inflammatory mediators in pulmonary vascular remodeling in a
`mouse model of pulmonary hypertension
`A study to quantify the number of circulating endothelial cells in patients with severe
`sepsis.
`Sponsor: Eli Lilly and Company - Investigator Initiated Grant
`Role: Principle Investigator
`Goals: Quantify and characterize abnormal circulating populations of endothelial cells in
`patients with severe sepsis and septic shock as a mechanism for multi organ failure
`syndrome
`Open-label Study to Evaluate the Safety and Efficacy of PRX—08066 in Patients with
`Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease.
`Sponsor: EPIX Pharmaceuticals - Investigator Initiated Study
`Role: Principle Investigator
`A randomized, double blind, placebo-controlled study of oral UT-lSC SR in Subjects with
`Pulmonary Arterial Hypertension
`Sponsor: United Therapeutics, Protocol No. TDE-PH-201
`Role: Principle Investigator
`A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging
`study of Cicletanine in Subjects with Pulmonary Arterial Hypertension
`Sponsor Gilead Sciences (Chair of Steering Committee)
`Role: Principle Investigator and Steering Committee Chairman
`Goals: Assess the efficacy and safety of a novel eNOS coupler, Cicletanine, in patients
`with pulmonary arterial hypertension.
`Brigham and Women’s Hospital Clinical Innovations Grant, Development of a
`Multidisciplinary DyspneafExercise Intolerance Center
`Role: Principle Investigator and Director
`
`6
`
`IPR2021-00406
`
`United Therapeutics EX2002
`Page 6 of 42
`
`IPR2021-00406
`United Therapeutics EX2002
`Page 6 of 42
`
`

`

`Goals: Establish of a comprehensive center to evaluate patients with resting or exertional
`dyspnea, bringing together a core group of clinical experts to collaboratively develop a
`streamlined efficient and effective approach to assessing and treating the patient with
`dySpnea.
`REVEAL Registry
`Sponsor: Actelion, Protocol No. RIV PH-408
`Role: Site Principle Investigator
`Goals: Development of a 5000 patient database of patients with PAH in order to better
`define the natural history of the disease.
`Study to assess the fate, safety, and efficacy of allogeneic mesenchymal stromal cells in a
`large animal model of precapillary pulmonary hypertension and right ventricular
`dysfunction
`United Therapeutics, Investigator Initiated Grant
`Role: Principle Investigator
`Goals: preclinical and clinical study to assess the safety and efficacy of allogeneic
`mesenchymal stromal cells infused into the right coronary artery in a large animal model of
`pulmonary hypertension and in patients with PAH and right ventricular dysfunction.
`Heme Oxygenase — IfCarbon Monoxide in Lung Vascular Injury
`Role: Site Principle Investigator
`NHLBI: R01HL06023412A1
`
`Goals: My role is specific to Aim 3 and includes an assessment of the efficacy of carbon
`monoxide in ameliorating pulmonary vascular remodeling via inhibition of inflammasome
`PCORI Clinical Data Research Network (CDRN) - Scalable Collaborative Infrastructure
`for Learning Healthcare System, PCORNet Rare Diseases Task Force, Harvard University
`Representative
`Goals: 29 clinical research data networks that together will form an ambitious new
`resource known as PCORnet, the National Patient-Centered Clinical Research Network.
`
`PCORnet will be a large, highly representative, national network for conducting clinical
`outcomes research.
`
`An open label uncontrolled study of the safety and efficacy of ambrisentan in patients with
`exercise induced pulmonary arterial hypertension.
`Gilead Science, Investigator Initiated Grant
`Role: Principle Investigator
`Goals: 6—month study to evaluate the effects of Ambrisentan (selective ETRA)
`administered orally on exercise capacity utilizing invasive cardiopulmonary exercise
`testing in patients with either exercise induced pulmonary arterial hypertension or diastolic
`dysfunction.
`Targeting metabolism to reverse RV dysfunction in PAH
`The Cardiovascular Medical Research and Education Fund
`
`Role: Co-Principle Investigator (Co-Principle Investigator with Dr. Yuchi Han at
`University of Pennsylvania)
`Goals: Multicenter study with colleagues at the University of Pennsylvania and the
`University of Maryland. This proposal will identify: (A) Key molecular and metabolic
`regulatory pathways that may be targeted for recovery of RV function in patients with
`PAH; and (B) Specific imaging, plasma, and metabolic markers to better guide prognosis
`and therapy of the RV dysfunction in PAH.
`
`2005-2012
`
`2013-2016
`
`2012-2016
`
`2014-2016
`
`2008-2016
`
`2013-2016
`
`Current
`
`lPR2021-00406
`
`United Therapeutics EX2002
`Page 7 of 42
`
`IPR2021-00406
`United Therapeutics EX2002
`Page 7 of 42
`
`

`

`2014-2019
`
`Integrated Endothelial Phenotyping to Redefine Pulmonary Hypertension.
`NHLBI U01 HLlZSZlS-Ol
`
`Role: Co-Principle Investigator (with Dr. Jane Leopold)
`Goals: performing patient phenotyping, which will lead to novel sub classifications of
`patients with pulmonary vascular-right ventricular disease, based on molecular and
`radiographic as well as clinical characteristics, which can be associated with specific
`molecular mechanisms of pathogenesis.
`
`2016-2019
`
`Molecular imaging of angiogenic activity in pulmonary arterial hypertension
`lROlHLl3l9lO—01(Yu)
`Role: Consultant
`
`Goals: Molecular imaging of angiogenic activity in pulmonary arterial hypertension
`
`Current Unfunded Projects
`2007-
`
`Principle Investigator
`Patient registry and biological database
`Ongoing collection of patient samples obtained during right heart catheterization and
`invasive CPET from the pulmonary artery and radial artery at rest, peak exercise, and one
`hour post exercise
`Report of Local Teaching and Training
`
`Teaching of Students in Courses
`
`Yale University School ofMedicine
`
`1995-1997
`
`1996-1999
`
`Yale Physician Associate Program, Introduction to Lecturer, Course Coordinator
`Clinical Medicine for Pulmonary Section
`lSt year students.
`Introduction to Clinical medicine for Pulmonary
`Medicine Section
`
`6 hours
`Lecturer
`
`2nd year medical students
`
`1997-1999
`
`Introduction to Clinical Medicine Course
`
`4 l-hour lectures over a 2 mos
`period
`Preclinical Tutor
`
`1998-1999
`
`4-hrsfwk for l6-wks
`2nd year medical students
`Introduction to Clinical Medicine Course, Cellular Lecturer
`and Molecular Basis of Acute Lung Injury
`2nd year medical students
`
`l-hour lecture
`
`Harvard Medical School
`
`2003-
`
`Introduction to Clinical Medicine Course, Human
`
`Preclinical Tutor
`
`2004-2008
`
`Systems, Respiratornyardiovascular Sections
`2'1d year medical students
`Respiratory Infections, Human Systems,
`Respiratornyardiovascular Sections
`2nd year medical students
`
`2-hrsfday 3-daysfwk for 8 wks
`Lecturer
`
`l-hr per year
`
`Formal Teachin of Residents Clinical Fellows and Research Fellows
`
`ost-docs
`
`lPR2021-00406
`
`United Therapeutics EX2002
`Page 8 of 42
`
`IPR2021-00406
`United Therapeutics EX2002
`Page 8 of 42
`
`

`

`199?- I 999
`
`Acute Care Lecture Series,
`
`Lecturer - Yale New Haven
`
`Internal Medicine Residency Program, Critical
`Care Summer Lecture Series
`
`Hospital
`2 1-hour lectures
`
`2000-2008
`
`Critical Care Lecture Series
`
`Lecturer — MGH
`
`2003-2008
`
`2003 -2 003
`
`2004-2009
`
`2005 -2 009
`
`Internal Medicine Residency Program
`Airway WorkshOp, airway management course;
`Pulmonary Critical Care Training Program
`Presented annually to incoming first year fellows
`in the Harvard Combined Program
`Introduction to Bronohoscopy Course, Indication,
`Contraindication and Consent
`
`Presented annually to incoming first year fellows
`throughout New England
`Pulmonary Vascular Physiology Clinical Training
`Includes training and supervision of fellows
`Cardiopulmonary Physiology Lecture Series
`
`Pulmonary Critical Care fellowship trainees
`
`Clinical Supervisogy and Training Responsibilities
`
`2 hours per month
`Course Director and Lecturer -
`HMS
`
`l-full day
`
`Lecturer - HMS
`
`1-full day
`
`Preceptor - HMS
`3-hours every week
`Lecturer and Organizer — HMS
`training program
`1-hour every week
`
`Yale University School ofMedicine
`] 996-1997
`
`Service Attending in the Medical Intensive Care
`Unit and Pulmonary Consultation Service, West
`Haven Veterans Hospital, Yale University Internal
`Medicine Training Program (1 Fellow, 1 Resident,
`1 Student)
`Service Attending in the Medical Intensive Care
`Unit and Pulmonary Consultation Service, West
`Haven Veterans HOSpital, Yale University Internal
`Medicine Training Program (1 Fellow, 1 Resident,
`1 Student)
`Attending Physician, Pulmonary Consultation
`Service, West Haven Veterans’ Administration
`Hospital
`Service Attending in the Medical Intensive Care
`Unit, Yale New Haven Hospital, Yale University
`Internal Medicine Training Program (1 Fellow, 3
`Residents, 3 Interns, 2 Students)
`Pulmonary Consultations Service Attending, Yale
`New Haven Hospital, Yale University Pulmonary
`Fellowship Training Program (1-2 Fellows, 1-2
`Residents, l-2 Students)
`Attending Physician, Medical Intensive Care Unit,
`YNHH
`
`Attending Physician, Pulmonary Consultation
`Service, YNHH
`
`1996-199?
`
`1996-1999
`
`1996-1999
`
`1997-1999
`
`19911999
`
`19911999
`
`One month
`
`One month
`
`One month
`
`Three months each year
`
`2 weeks each year
`
`3 months each year
`
`2 months each year
`
`IPR2021-00406
`
`United Therapeutics EX2002
`Page 9 of 42
`
`IPR2021-00406
`United Therapeutics EX2002
`Page 9 of 42
`
`

`

`2000-2001
`
`New England Medical Center
`2000 — 2001
`Pulmonary Service Attending, Tufts University
`Internal Medicine Training Program (1 Fellow, 1
`Resident, 2 Interns, and 1-2 Students)
`Service Attending in the Medical Intensive Care
`Unit, New England Medical Center, Tufts
`University Internal Medicine Training Program (1
`Fellow, 5 Residents, 3 interns, and 1-2 Students)
`Attending Physician, Medical Intensive Care Unit,
`NEMC
`
`2000-2001
`
`Four weeks each year for 2 years
`
`Three months each year for two
`years
`
`2 months
`
`Winchester Hospita!
`2000-2001
`Attending Physician Medical Intensive Care Unit,
`Winchester Hospital
`
`2 months per year
`
`Harvard Medical Schoolr
`
`2002-2009
`
`2002-2009
`
`2003-2009
`
`2009-
`
`Pulmonary Consult Attending, Massachusetts
`General Hospital, Harvard Medical School
`Pulmonary Critical Care Training Program (2
`Fellows, 1-2 Residents, and 1-2 Students)
`Critical Care Attending, Medical Intensive Care
`Unit, Massachusetts General Hospital, Harvard
`Medical School Internal Medicine and Pulmonary
`Critical Care Training Program (1 Fellow, 3
`Residents, 3 interns, and 1—2 Students)
`Pulmonary Clinic, Clinical Preceptor, Internal
`Medicine Residency Program (15‘, 2nd and 3rd year
`medical residents)
`Pulmonary Vascular Disease and Critical Care
`Attending, Brigham and Women’s Hospital,
`Harvard Medical School Anesthesiology, Ob-Gyn,
`Surgery, Internal Medicine, and Pulmonary
`Critical Care Training Programs (1 Fellow, 4
`Residents, 1 interns)
`
`Two weeks each year
`
`Three months each year
`
`2 and a half days per week
`
`Two months each year
`
`Laboratory and Other Research Sunervisofl and Training Resgonsibilities
`
`Massachusetts Genera! Hospital
`
`2001- 2010
`
`Principle Investigator Pulmonary Research
`Laboratory
`
`15% effort
`
`Formally Sugervised Trainees
`
`1997-1998
`
`Jonathan Come, MBBS, Yale School of Medicine. Current position: Senior Consultant,
`Queens University Medical Center Nottingham, England, Funded by the Medical
`Research Council of the United Kingdom
`Research Advisor, 2 years. IL—13 stimulates vascaiar enldoth'ehiatJr cell growth factor and
`protects against hyperoxic lung injury.
`
`10
`
`IPR2021-00406
`
`United Therapeutics EX2002
`Page 10 of 42
`
`IPR2021-00406
`United Therapeutics EX2002
`Page 10 of 42
`
`

`

`1996-1999
`
`2001-2002
`
`2003-2005
`
`2003-2007
`
`2005-2008
`
`2006-2008
`
`Nicholas Ward, M.D., Yale School of Medicine. Current position: Associate Professor,
`Brown University School of Medicine.
`Research Adviser, 2 years. Evaluation oflL-6 induced protection in hyperoxic acute
`lung injury using an overexpression transgenic model
`Hubert Chen, M.D.,MPH, Current position: Medical Director at Genentech.
`Research Advisor, 1 year. Potential Cost-Efiectiveness of Epoprostenol as First-line
`Therapy for Pulmonary Arterial Hypertension.
`Pe—Shun Lee, M.D., Current position in industry.
`Research Advisor, 2 years, Plasma Gelsolin is a Critical ProkSurvival Factor in Sepsis;
`Evaluation of the role ofcytoskeletal components and cellular debris in the initiation of
`the systemic inflammatory response. Second Prize 2005 New England Respiratory
`Research Competition Award, Research Advisor, Current position Translational
`Medicine Expert at Novartis Institutes for BioMedi cal Research
`George Barker, M.D., Ph.D. Current position, Clinical faculty Harvard Medical School,
`Mount Auburn Hospital, Primary Mentor, Research Advisor, 3 years. DNA Damage in
`Hyperoxic Lung Injury. Recipient of the GSK Mentored Pulmonary Research
`Fellowship 2004-2005, First Prize 2005 New England ReSpiratory Research
`Competition Award.
`James Tolle, M.D., Current position, Assistant Professor, Vanderbilt University School
`of Medicine, Research Advisor, 3- years. Abnormal Systemic Oxygen Extraction in
`Pulmonary Hypertension During Incremental Exercise.
`M. Kathryn E. Steiner, M.D., Current position, Staff Pulmonologist, New England
`Baptist Hospital, Primary Mentor, Research Adviser, 2-years. Role ofIL-6 in the
`Pathogenesis ofPulmonary Hypertension.
`2005- 2010 Narasiah Kelliputi, Ph.D., Current position, Associate Professor, University of South
`Florida, Primary Mentor, 5-years. Role ofIL-6 in protection from cell death. Recipient
`of an AHA research award in lung injury, FASEB Young Investigator Award, and
`successfully R01 funded
`Bart Boerrigter, M.D., Ph.D., Current Position, Clinical fellowship in pulmonary
`medicine, VU University Medical Center, Amsterdam. Research mentor as part of pre-
`dectoral research, Pulmonary hemocbmamics and exercise in chronic obstructive
`pulmonary disease.
`2012-2014 Mario Santos, M.D., Ph.D., Current position, Department of Physiology and
`Cardiothoracic Surgery, Cardiovascular R&D Unit, Faculty of Medicine, University of
`Porto, Portugal, Research mentor, Study of the physiologic limits to aerobic capacity in
`heart failure with preserved ejection fraction, and pulmonary hypertension.
`2014-2015 Manyoo Agarwal, MBBS, Current position, Resident physician, Department of Internal
`Medicine, University of Tennessee, Memphis, Research Fellowship in pulmonary
`vascular disease and exercise physiology. Research Mentor as part of postdoctoral
`research fellowship, Treatment of Group-3 PH with pulmonary vasodilator therapy.
`Rudolph Oliveira, M.D., Research Fellowship in pulmonary vascular disease and
`exercise physiology. Research Mentor as part of postdoctoral research fellowship,
`Hemodynamic and physiologic characteristics ofpatients with connective tissue disease
`related lung disease
`2014-2015 Wei Huang, M.D., PhD, Research Fellowship and Clinical Observership funded by the
`State Hospital In Chongqing China. Research and Clinical mentor, Outcomes ofpatients
`with EPAH and HFpEF
`
`2013
`
`2014-2015
`
`l l
`
`IPR2021-00406
`
`United Therapeutics EX2002
`Page 11 of 42
`
`IPR2021-00406
`United Therapeutics EX2002
`Page 11 of 42
`
`

`

`2014-2016
`
`2014-2017
`
`201 5-
`
`present
`
`2016-
`
`present
`
`201 2-
`
`present
`
`Roza Badreslam, M.D., Erin—SchroClinger-Fellowship, Austrian Science Fund. Research
`Mentor, post—doctoral research fellowship, Right ventricular remodeiing and
`mitochondriaifunction
`Tamara Roldan Sevilla, Pro—Doctoral Student, Universidad Autonoma De Madrid
`
`Facultad De Medicina, Departamento De Medicina, Doctoral Thesis: Safety Evaiuation
`ofOrai Anticoaguiation in Puimonary A rteriai Hypertension: Observationai Study of
`Patients Followed in Two Puimonaty Hypertension i'i’eferrair Centers in Spain and
`United States.
`
`Marianna Faria Urbina, M.D., Research Fellowship in pulmonary vascular disease and
`exercise physiology. Research Mentor, Physiologic assessment ofprecapiiiaty
`puimonary hypertension in the setting ofhypoxic lung disease.
`Inderjit Singh, M.D., Pulmonary Vascular Disease Fellowship, 2 years, Primary Mentor,
`Evaluation ofR V-PA coupling during exercise in patients with Group-2 pulmonary
`hypertension.
`Andrew Schissler, M.D., Primary Mentor, Research Mentor, 2 years, Evaiuation of
`outcomes in patients with submassive pulmonary emboiisrn.
`
`Formal Teaching of Peers leg, CME and other continuing education courses!
`
`No presentations below were Sponsored by outside entities
`
`2002
`
`2002
`
`2002
`
`2003
`
`2003
`
`Bioterrorism Preparedness and Response
`
`Harvard Medical School, Continuing Medical Education,
`Pulmonary Critical Care Postgraduate Course, MGH
`
`Single presentation
`
`Cambridge, MA
`
`Bioterrorism Preparedness and ReSponse. Harvard University Cambridge MA
`Wide Health Policy Program Core Seminar Series, Public Health
`Section, Kennedy School of Government, Harvard University
`
`73-year-old woman with Pneumonia and Respiratory Failure. Boston, MA
`Clinical Pathologic Conference of the Massachusetts General
`Hospital and Harvard Medical School
`
`Severe Sepsis and Septic Shock: New Options for Treatment. Boston, MA
`Anesthesia Critical Care Grand Rounds, Beth Israel Deaconess
`Medical Center and Harvard Medical School
`
`Pulmonary Arterial Hypertension, Evaluation and Management. Boston, MA
`Medical Grand Rounds, Massachusetts General Hospital
`
`2003, 2004
`
`Fluid Resuscitation in Septic Shock
`
`Harvard Medical School, Continuing Medical Education,
`Pulmonary Critical Care Postgraduate Course, MGH
`
`Single presentation
`
`Cambridge, MA
`
`2003, 2004
`
`Severe Sepsis: New Options in the Treatment of Sepsis
`
`Single presentation
`
`Harvard Medical School, Continuing Medical Education,
`Pulmonary Critical Care Postgraduate Course, MGH
`
`Cambridge, MA
`
`2003, 2004
`
`Pulmonary Arterial Hypertension
`
`Single presentation
`
`Harvard Medical School, Continuing Medical Education, Internal Cambridge, MA
`Medicine Postgraduate Review Course, MGH
`
`2004
`
`Acute Respiratory Distress Syndrome
`
`Single presentation
`
`12
`
`IPR2021-00406
`
`United Therapeutics EX2002
`Page 12 of 42
`
`IPR2021-00406
`United Therapeutics EX2002
`Page 12 of 42
`
`

`

`Harvard Medical School Continuing Medical Education,
`Intensive Review of Internal Medicine, Postgraduate Review
`Course, Brigham and Women’s Hospital
`
`Boston, MA
`
`2004, 2006,
`
`2007,
`
`Fluid Resuscitation in Vasodilatory Shock; Crystalloids versus
`Colloids
`
`Harvard Medical School Continuing Medical Education,
`Pulmonary Critical Care Postgraduate Course, MGH
`
`Cambridge, MA
`
`Pulmonary Arterial Hypertension: Evaluation and Management
`
`2005, 2006,
`2007, 2008
`
`Harvard Medical School Continuing Medical Education:
`
`Cambridge, MA
`
`0
`0
`
`Internal Medicine Postgraduate Review Course (2005)
`Pulmonary Critical Care Postgraduate Course (2008), MGH
`
`Update on Therapy in Pulmonary Arterial Hypertension
`
`Single presentation
`
`Harvard Medical School Continuing Medical Education,
`Advanced Heart and Lung Disease, MGH
`
`Inflammation and Pulmonary Vascular Remodeling. Harvard
`Medical School Combined Pulmonary Critical Care Grand
`Rounds
`
`Cambridge, MA
`
`Boston MA
`
`Evaluation and Management of Pulmonary Arterial Hypertension
`for the General Internist
`
`Single presentation
`
`Harvard Medical School Continuing Medical Education, Internal
`Medicine Postgraduate Review Course, MGH
`
`Cambridge, MA
`
`Simply Speaking - Post Conference Update: American Thoracic
`Society
`
`Pulmonary Arterial Hypertension Educator’s CME Lecture
`Series
`
`Boston, MA
`
`(Unrestricted Industry Grants)
`
`Evolving Management of ARDS; Less is Definitely Better.
`Pediatric Pulmonary Conference, Massachusetts General Hospital
`
`Boston, MA
`
`2006
`
`2007
`
`2007
`
`2007
`
`200'?
`
`2008, 2009
`
`Fluid Resuscitation in Shock; Crystalloids and Colloids, is there
`any difference?
`
`Single presentation
`
`2009
`
`2009
`
`2009
`
`Harvard Medical School Continuing Medical Education,
`Pulmonary Critical Care Postgraduate Course, MGH
`
`Pulmonary Arterial Hypertension: Chronic and Acute and
`Management
`
`Harvard Medical School Continuing Medical Education,
`Pulmonary Critical Care Postgraduate Course, MGH
`
`Cambridge, MA
`
`Single presentation
`
`Cambridge, MA
`
`Pulmonary Arterial Hypertension; A Systemic Disease.
`Rheumatology Grand Rounds, Massachusetts General Hospital
`
`Systemic Issues in PHT: The View from the Rest of the Body.
`Congenital Heart Disease-Associated Pulmonary Hypertension: A
`Two Day “Master Class”, Children’s Hospital
`
`Boston, MA
`
`Boston, MA
`
`13
`
`IPR2021-00406
`
`United Therapeutics EX2002
`Page 13 of 42
`
`IPR2021-00406
`United Therapeutics EX2002
`Page 13 of 42
`
`

`

`2010
`
`2010
`
`2010
`
`2011
`
`2012
`
`2013
`
`2013
`
`2015
`
`2016
`
`2016
`
`2016
`
`2016
`
`2017r
`
`2017
`
`Pulmonary Arterial Hypertension — Management in the Acute Boston, MA
`Setting. Anesthesia Critical Care Grand Rounds, Brigham and
`Wome